撕掉肿瘤细胞“隐身衣”！我国科学家在攻克癌症免疫耐受难题上有新突破

Core Insights - A new protein-targeted degradation technology developed by a team from Peking University aims to address the challenge of tumor cells evading the immune system, effectively transforming these "invisible enemies" into identifiable targets for treatment [1][2]. Group 1: Technology and Mechanism - The innovative molecule named "intra-tumoral vaccine chimeric" (iVAC) allows for the entry into tumor cells without relying on specific surface markers, enabling the destruction of PD-L1 proteins that inhibit immune activation [2][3]. - iVAC processes and presents active antigen fragments on the surface of tumor cells, effectively providing them with an "identity label" that the immune system can recognize [2]. Group 2: Efficacy and Advantages - Compared to traditional immune checkpoint blockade therapies, iVAC demonstrates significant anti-tumor effects by enhancing the immune system's ability to recognize and eliminate tumor cells, while also activating effector T cells that can target virus-infected tumor cells [3]. - The small size of the iVAC molecule allows it to penetrate dense solid tumors effectively, contributing to its strong anti-tumor efficacy [3]. Group 3: Future Prospects - The research team is actively working on the clinical translation of this promising technology, which has been recognized as a significant theoretical foundation for the development of new treatment methods [3].